ClinicalTrials.gg
RecruitingNCT07610798Updated Jun 10, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

A Phase 1/2 interventional study of INV-8989 in Advance Solid Tumors, Colon and Rectal Cancer and Non - Small Cell Lung Cancer NSCLC, sponsored by Shenzhen Ionova Life Sciences Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Shenzhen Ionova Life Sciences Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
178
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
121st of 373
178 · median 100
Started
2026
with 50 others
Phase 1/2
12 of 463
7 open now
Primary completion
2029-05
later than 240 of 266 live
Registered
435th of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 121st largest by planned enrollment of the 373 interventional ones that give a count, is one of 51 that started in 2026, is one of 12 in phase 1/2, reaches primary completion later than 240 of the 266 other live ones, and was the 435th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

222 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.

Read the detailed description

This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.

The entire study consists of two parts: Phase 1 for dose escalation and Phase 2 for dose expansion and indication exploration.

Phase 1 dose escalation of INV-8989 follows a real time monitored, PK/PD and safety guided scheme with an accelerated titration plus traditional 3+3 design for DLT assessment.

Phase 2 aims to reassure the safety profile and better define efficacy. Phase 2 consists of Phase 2a and Phase 2b.

Phase 2a study aims to further confirm the safety profile of INV-8989 through a larger number of patients, clarify its PK characteristics and preliminary efficacy, and optimize the recommended Phase 2 dose (RP2D).

The Phase 2b study aims to explore the anti-tumor efficacy of INV-8989 in the patients with different types of advanced solid tumors harboring the KRAS G12D mutation, and those who have failed previous standard treatments.

03

Conditions studied

  • Advance Solid Tumors
  • Colon and Rectal Cancer
  • Non - Small Cell Lung Cancer NSCLC
  • Pancreatic Adenocarcinoma Advanced or Metastatic
  • Ovarian Cancer
  • Endometrial Cancer
  • Biliary Cancers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained.
  2. Adult patients aged ≥ 18 years.
  3. Patients with or cytologically confirmed locally advanced, unresectable, or solid tumors harboring the KRAS G12D mutations.
  4. Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor .
  5. Have 1.1-defined .
  6. Has a of > 3 months.
  7. performance status 0-1.
  8. Adequate marrow, liver and kidney function.
  9. Meet the study's specified requirements.
  10. Meet protocol-specified requirements.

Exclusion criteria

Exclusion Criteria:

  1. Have protocol-defined toxicities within 28 days before the start of study treatment.
  2. Have a second primary .
  3. Patients with known to the study drug or any of its components.
  4. Prior history of receiving targeted therapy with specific KRAS G12D inhibitors/degraders or pan-RAS inhibitors/degraders for KRAS G12D mutation.
  5. Has undergone major surgery within 28 days prior to the first dose of study drug.
  6. Patients with symptomatic brain or .
  7. Patients with other severe and persistent underlying medical conditions as assessed by the Investigator.
  8. Have protocol-defined cardiovascular diseases.
  9. Prolonged interval.
  10. Patients with dyspnea at rest secondary to complications of advanced malignancy, or requiring continuous oxygen therapy due to other medical conditions.
  11. Patients with active pulmonary tuberculosis (TB).
  12. Patients with a known history of interstitial lung disease (ILD).
  13. Patients with a known history of allogeneic solid organ transplantation or hematopoietic stem cell transplantation.
  14. Have experienced a severe concurrent infection within 28 days prior to the first dose of study drug.
  15. Patients with congenital or acquired immunodeficiency.
  16. Female patients in pregnancy or lactation period.
  17. Patients with concomitant diseases or conditions deemed by the Investigator likely to interfere with protocol compliance.
  18. Patients unwilling or unable to comply with protocol-specified procedures.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
178 participants (estimated)

Study arms

  • Experimental
    Phase 1 INV-8989 Dose escalation Dose level 1

    Drug: INV-8989

  • Experimental
    Phase 1 INV-8989 Dose escalation Dose level 2

    Drug: INV-8989

  • Experimental
    Phase 1 INV-8989 Dose escalation Dose level 3

    Drug: INV-8989

  • Experimental
    Phase 1 INV-8989 Dose escalation Dose level 4

    Drug: INV-8989

  • Experimental
    Phase 1 INV-8989 Dose escalation Dose level 5

    Drug: INV-8989

  • Experimental
    Phase 1 INV-8989 Dose escalation Dose level 6

    Drug: INV-8989

  • Experimental
    Phase 1 INV-8989 Dose escalation Dose level 7

    Drug: INV-8989

  • Experimental
    Phase 1 INV-8989 Dose escalation Dose level 8

    Drug: INV-8989

  • Experimental
    Phase 2a INV-8989 Dose level 1

    Drug: INV-8989

  • Experimental
    Phase 2a INV-8989 Dose level 2

    Drug: INV-8989

  • Experimental
    Phase 2b INV-8989 cohort A

    Drug: INV-8989

  • Experimental
    Phase 2b INV-8989 cohort B

    Drug: INV-8989

  • Experimental
    Phase 2b INV-8989 cohort C

    Drug: INV-8989

  • Experimental
    Phase 2b INV-8989 cohort D

    Drug: INV-8989

Interventions

  • DrugINV-8989

    INV-8989 is admistered once weekly

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of participants with treatment-emergent adverse events (TEAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    The number and percentage of participants with at least one TEAE will be summarized by severity grade and relationship to study drug.

    Time frame: 12 months

  2. Phase 1: Maximum tolerated dose (MTD)

    The highest dose level at which at least 6 patients have been treated and less than 33% of patients experienced a DLT.

    Time frame: Within first 21 days of treatment

  3. Phase 1: Recommended dose range (RDR) and/or Recommended Phase Ⅱ dose (RP2D)

    The RDR and/or RP2D will be determined based on the PK and PD data, the preliminary clinical activity of INV-8989, as well as the incidence rate and nature of the toxicities observed in subsequent cycles beyond Cycle 1.

    Time frame: 12 months

  4. Phase 2: Evaluate overall response rate (ORR)

    To evaluate ORR per RECIST v1.1

    Time frame: 12 months

Secondary outcomes

  1. Phase 1: Determine the pharmacokinetics (PK) using AUC of INV-8989

    To determine the (PK) using AUC of INV-8989 after a single dose and at steady state after multiple doses

    Time frame: 12 months

  2. Phase 1: Determine the PK using Cmax of INV-8989

    Determine the PK using Cmax of INV-8989 after a single dose and at steady state after multiple doses

    Time frame: 12 months

  3. Phase 1: Evaluate overall response rate (ORR)

    To evaluate ORR per RECIST v1.1

    Time frame: 12 months

  4. Phase 1: Evaluate progression free survival (PFS)

    To evaluate PFS per RECIST v1.1

    Time frame: 12 months

  5. Phase 2: Evaluate progression free survival (PFS)

    To evaluate PFS per RECIST v1.1

    Time frame: 12 months

  6. Phase 2: Determine the PK using AUC of INV-8989

    Determine the PK using AUC of INV-8989 after a single dose and at steady state after multiple doses

    Time frame: 12 months

  7. Phase 2: Determine the PK using Cmax of INV-8989

    To determine the PK using Cmax of INV-8989 after a single dose and at steady state after multiple doses

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

Of 37 phase 1/2 interventional studies under Rectal Neoplasms, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 28, 2026
StartActual
Jun 1, 2026
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07610798
Lead sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Jun 1, 2026
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jun 10, 2026

Study contacts

Yi Zhu, MD, MBA
Contact
yi.zhu@ionovabio.com
1 908 240 7514

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion